{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:26:47Z","timestamp":1792794407968,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jaad.2023.05.074","type":"journal-article","created":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T14:10:19Z","timestamp":1686406219000},"page":"358-367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Systemic calcineurin inhibitors tacrolimus and voclosporin: A review of off-label dermatologic uses"],"prefix":"10.1016","volume":"90","author":[{"given":"Annie","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jaad.2023.05.074_bib1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1358\/dnp.2003.16.5.829315","article-title":"Molecular actions of calcineurin inhibitors","volume":"16","author":"Hamawy","year":"2003","journal-title":"Drug News Perspect"},{"issue":"10","key":"10.1016\/j.jaad.2023.05.074_bib2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/FPC.0b013e328364db84","article-title":"PharmGKB summary: cyclosporine and tacrolimus pathways","volume":"23","author":"Barbarino","year":"2013","journal-title":"Pharmacogenet Genomics"},{"issue":"7","key":"10.1016\/j.jaad.2023.05.074_bib3","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1093\/ndt\/gfn004","article-title":"Efficacy and safety of tacrolimus compared with ciclosporin A in renal transplantation: three-year observational results","volume":"23","author":"Kr\u00e4mer","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.jaad.2023.05.074_bib4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1529-8019.2007.00137.x","article-title":"Systemic ciclosporin and tacrolimus in dermatology","volume":"20","author":"Madan","year":"2007","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.jaad.2023.05.074_bib5","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdv.14888","article-title":"Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II","volume":"32","author":"Wollenberg","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.jaad.2023.05.074_bib6","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/all.12313","article-title":"The EAACI\/GA(2) LEN\/EDF\/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update","volume":"69","author":"Zuberbier","year":"2014","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.jaad.2023.05.074_bib78","first-page":"36","article-title":"The effect of tacrolimus on lower extremity ulcers: a case study and review of the literature","volume":"54","author":"Miller","year":"2008","journal-title":"Ostomy Wound Manage"},{"issue":"6","key":"10.1016\/j.jaad.2023.05.074_bib79","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/ced.12858","article-title":"Oral tacrolimus: a treatment option for recalcitrant erosive lichen planus","volume":"41","author":"Yeo","year":"2016","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.05.074_bib80","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jdcr.2017.02.022","article-title":"Systemic tacrolimus in the treatment of recalcitrant mucosal lichen planus","volume":"3","author":"Chen","year":"2017","journal-title":"JAAD Case Rep"},{"issue":"2","key":"10.1016\/j.jaad.2023.05.074_bib82","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000314155","article-title":"Recalcitrant pemphigus vulgaris responding to systemic tacrolimus","volume":"221","author":"B\u00fcsing","year":"2010","journal-title":"Dermatology (Basel)"},{"issue":"1","key":"10.1016\/j.jaad.2023.05.074_bib83","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3109\/09546634.2013.873763","article-title":"Assessment of the adjuvant effect of tacrolimus in the management of pemphigus vulgaris: a randomized controlled trial","volume":"26","author":"Dastgheib","year":"2015","journal-title":"J Dermatol Treat"},{"issue":"17","key":"10.1016\/j.jaad.2023.05.074_bib7","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJM199410273311702","article-title":"FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation","volume":"331","year":"1994","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jaad.2023.05.074_bib8","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1600-6143.2004.00427.x","article-title":"Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile","volume":"4","author":"Artz","year":"2004","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.jaad.2023.05.074_bib9","first-page":"589","article-title":"Comparison of efficacy of tacrolimus versus cyclosporine in childhood steroid-resistant nephrotic syndrome","volume":"26","author":"Shah","year":"2016","journal-title":"J Coll Physicians Surg Pak"},{"issue":"11","key":"10.1016\/j.jaad.2023.05.074_bib10","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1097\/01.tp.0000181195.67084.94","article-title":"Tacrolimus-induced alopecia in female kidney-pancreas transplant recipients","volume":"80","author":"Tricot","year":"2005","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.jaad.2023.05.074_bib11","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1046\/j.1600-6143.2003.00372.x","article-title":"New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis","volume":"4","author":"Heisel","year":"2004","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.jaad.2023.05.074_bib12","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1097\/TP.0000000000001243","article-title":"Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology: comparison of cyclosporine and tacrolimus eras","volume":"100","author":"Nankivell","year":"2016","journal-title":"Transplantation"},{"issue":"25","key":"10.1016\/j.jaad.2023.05.074_bib13","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jaad.2023.05.074_bib15","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/archderm.1992.01680160065005","article-title":"Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis","volume":"128","author":"Jegasothy","year":"1992","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.05.074_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/1203475415616964","article-title":"Pilot study to evaluate the efficacy and safety of oral tacrolimus in adult patients with refractory severe plaque psoriasis","volume":"20","author":"Mittal","year":"2016","journal-title":"J Cutan Med Surg"},{"issue":"4","key":"10.1016\/j.jaad.2023.05.074_bib17","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/archderm.1996.03890280081011","article-title":"Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study","volume":"132","year":"1996","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.05.074_bib18","first-page":"3325","article-title":"Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases","volume":"23","author":"Nikolaidis","year":"1991","journal-title":"Transplant Proc"},{"issue":"6","key":"10.1016\/j.jaad.2023.05.074_bib19","first-page":"3330","article-title":"Influence of FK 506 on T lymphocytes, langerhans' cells and the expression of cytokine receptors and adhesion molecules in psoriatic skin lesions: a preliminary study","volume":"23","author":"Thomson","year":"1991","journal-title":"Transplant Proc"},{"issue":"2","key":"10.1016\/j.jaad.2023.05.074_bib20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2249.1995.tb05525.x","article-title":"IL-8\/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy","volume":"99","author":"Lemster","year":"1995","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2023.05.074_bib21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/dth.12176","article-title":"Combination of everolimus and tacrolimus: a potentially effective regimen for recalcitrant psoriasis","volume":"28","author":"Wei","year":"2015","journal-title":"Dermatol Ther"},{"issue":"4","key":"10.1016\/j.jaad.2023.05.074_bib26","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jaad.2011.10.033","article-title":"Open-label, pilot study examining sequential therapy with oral tacrolimus and topical tacrolimus for severe atopic dermatitis","volume":"67","author":"Keaney","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2023.05.074_bib27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1440-0960.2011.00789.x","article-title":"Poor efficacy of oral tacrolimus in the treatment of severe generalized atopic eczema in adults: a small retrospective case series","volume":"53","author":"Lee","year":"2012","journal-title":"Australas J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.05.074_bib28","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1067\/mai.2003.1509","article-title":"Oral tacrolimus for severe recalcitrant atopic eczema","volume":"111","author":"Schroer","year":"2003","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2023.05.074_bib29","doi-asserted-by":"crossref","first-page":"AB64","DOI":"10.1016\/j.jaad.2014.01.265","article-title":"Oral tacrolimus in treatment of severe atopic dermatitis","volume":"70","author":"Short","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.05.074_bib33","first-page":"3328","article-title":"Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum","volume":"23","author":"Abu-Elmagd","year":"1991","journal-title":"Transplant Proc"},{"issue":"2","key":"10.1016\/j.jaad.2023.05.074_bib34","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1445-5994.1996.tb00896.x","article-title":"Resolution of pyoderma gangrenosum using tacolimus (FK-506)","volume":"26","author":"Cooley","year":"1996","journal-title":"Aust N Z J Med"},{"issue":"9","key":"10.1016\/j.jaad.2023.05.074_bib35","doi-asserted-by":"crossref","first-page":"783","DOI":"10.7326\/0003-4819-128-9-199805010-00031","article-title":"Tacrolimus to treat pyoderma gangrenosum resistant to cyclosporine","volume":"128","author":"D'Inc\u00e0","year":"1998","journal-title":"Ann Intern Med"},{"issue":"4 Pt 1","key":"10.1016\/j.jaad.2023.05.074_bib36","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S0190-9622(98)70020-9","article-title":"Efficacy of tacrolimus (FK 506) in idiopathic treatment-resistant pyoderma gangrenosum","volume":"39","author":"Weichert","year":"1998","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.05.074_bib37","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1046\/j.1365-2133.1999.02746.x","article-title":"Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosum","volume":"140","author":"Jolles","year":"1999","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.05.074_bib38","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1046\/j.1365-2133.1999.02745.x","article-title":"Recalcitrant pyoderma gangrenosum treated with systemic tacrolimus","volume":"140","author":"Jolles","year":"1999","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2023.05.074_bib39","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/00054725-200407000-00014","article-title":"Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus (FK506) in ulcerative colitis","volume":"10","author":"Baumgart","year":"2004","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"10.1016\/j.jaad.2023.05.074_bib40","first-page":"308","article-title":"Recalcitrant cases of pyoderma gangrenosum, responding dramatically to systemic tacrolimus","volume":"152","author":"Sadati","year":"2017","journal-title":"G Ital Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2023.05.074_bib41","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/25785826.2018.1531194","article-title":"Successful treatment with tacrolimus of refractory pyoderma gangrenosum with pouchitis after restorative proctocolectomy for ulcerative colitis","volume":"41","author":"Satake","year":"2018","journal-title":"Immunol Med"},{"issue":"5","key":"10.1016\/j.jaad.2023.05.074_bib42","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1111\/pde.13471","article-title":"Pyoderma gangrenosum in an infant: a case report and review of the literature","volume":"35","author":"Crouse","year":"2018","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2023.05.074_bib43","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jdcr.2021.12.020","article-title":"Oral tacrolimus for ocular involvement in pediatric neutrophilic dermatoses","volume":"21","author":"Swaffar","year":"2022","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.jaad.2023.05.074_bib46","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaad.2004.09.023","article-title":"Tacrolimus in the treatment of severe chronic idiopathic urticaria: an open-label prospective study","volume":"52","author":"Kessel","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.05.074_bib47","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/j.jaip.2018.12.023","article-title":"Effectiveness and safety of oral tacrolimus in refractory chronic urticaria","volume":"7","author":"Dorman","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.jaad.2023.05.074_bib49","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/ibd.20970","article-title":"Efficacy of oral tacrolimus on intestinal Behcet's disease","volume":"16","author":"Matsumura","year":"2010","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.jaad.2023.05.074_bib51","first-page":"802","article-title":"A phase II study of FK506 (tacrolimus) on refractory uveitis associated with Beh\u00e7et\u2019s disease and allied conditions","volume":"35","author":"Sakane","year":"1995","journal-title":"Ryumachi"},{"issue":"2","key":"10.1016\/j.jaad.2023.05.074_bib52","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1076\/ocii.6.2.101.4051","article-title":"Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis","volume":"6","author":"Kilmartin","year":"1998","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"10.1016\/j.jaad.2023.05.074_bib53","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0161-6420(99)90156-2","article-title":"Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine","volume":"106","author":"Sloper","year":"1999","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.jaad.2023.05.074_bib54","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2169\/internalmedicine.56.7808","article-title":"Successful treatment of Beh\u00e7et\u2019s disease associated with acute myeloid leukemia with myelodysplasia-related changes using azacitidine and tacrolimus before allogeneic hematopoietic stem cell transplantation","volume":"56","author":"Nakamura","year":"2017","journal-title":"Intern Med"},{"issue":"1","key":"10.1016\/j.jaad.2023.05.074_bib55","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1378\/chest.104.1.309","article-title":"Pulmonary infiltrates recovered by FK506 in a patient with Beh\u00e7et\u2019s disease","volume":"104","author":"Koga","year":"1993","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.jaad.2023.05.074_bib59","first-page":"3225","article-title":"FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation","volume":"23","author":"Tzakis","year":"1991","journal-title":"Transplant Proc"},{"issue":"6","key":"10.1016\/j.jaad.2023.05.074_bib60","first-page":"885","article-title":"FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and\/or other immunosuppressants. Japanese FK506 BMT Study Group","volume":"15","author":"Kanamaru","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jaad.2023.05.074_bib61","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/00007691-199804000-00017","article-title":"Successful therapy of refractory graft versus host disease with tacrolimus and Psoralen plus ultraviolet light","volume":"20","author":"Jubran","year":"1998","journal-title":"Ther Drug Monit"},{"issue":"5","key":"10.1016\/j.jaad.2023.05.074_bib62","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/sj.bmt.1701936","article-title":"Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus","volume":"24","author":"Mookerjee","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jaad.2023.05.074_bib63","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S1083-8791(00)70026-7","article-title":"Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease","volume":"6","author":"Carnevale-Schianca","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaad.2023.05.074_bib64","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bbmt.2003.12.245","article-title":"Tacrolimus in combination with steroids for the treatment of chronic GvHD","volume":"10","author":"Jesus","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jaad.2023.05.074_bib65","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2141.2005.05616.x","article-title":"Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease","volume":"130","author":"Couriel","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaad.2023.05.074_bib14","first-page":"153","article-title":"Tacrolimus for the management of psoriasis: clinical utility and place in therapy","volume":"6","author":"Malecic","year":"2016","journal-title":"Psoriasis (Auckl)"},{"key":"10.1016\/j.jaad.2023.05.074_bib22","article-title":"Systemic treatments for eczema: a network meta-analysis","volume":"11","author":"Sawangjit","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.jaad.2023.05.074_bib23","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents","volume":"71","author":"Sidbury","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.05.074_bib24","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.anai.2018.07.042","article-title":"Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2023.05.074_bib25","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.anai.2019.10.013","article-title":"Increased cardiovascular and atherosclerosis markers in blood of older patients with atopic dermatitis","volume":"124","author":"He","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"10","key":"10.1016\/j.jaad.2023.05.074_bib30","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1002\/art.20559","article-title":"Therapeutic management of pyoderma gangrenosum","volume":"50","author":"Ehling","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.jaad.2023.05.074_bib31","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jaad.2004.10.006","article-title":"Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients","volume":"53","author":"Reichrath","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.05.074_bib32","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1517\/14740338.6.5.479","article-title":"The use of tacrolimus in the treatment of inflammatory bowel disease","volume":"6","author":"Chow","year":"2007","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"10.1016\/j.jaad.2023.05.074_bib44","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/ACI.0b013e32835571f6","article-title":"Calcineurin inhibitors in chronic urticaria","volume":"12","author":"Trojan","year":"2012","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2023.05.074_bib45","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jaip.2016.08.010","article-title":"The comparative safety of multiple alternative agents in refractory chronic urticaria patients","volume":"5","author":"Seth","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.jaad.2023.05.074_bib48","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/2040622314523062","article-title":"Update on the therapy of Beh\u00e7et disease","volume":"5","author":"Saleh","year":"2014","journal-title":"Ther Adv Chronic Dis"},{"issue":"2","key":"10.1016\/j.jaad.2023.05.074_bib50","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/00004836-200003000-00006","article-title":"Gastrointestinal manifestations of Behcet's disease","volume":"30","author":"Bayraktar","year":"2000","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"10.1016\/j.jaad.2023.05.074_bib56","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","article-title":"Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"7","author":"Penack","year":"2020","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.jaad.2023.05.074_bib57","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.bmt.1703097","article-title":"Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation","volume":"28","author":"Hiraoka","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jaad.2023.05.074_bib58","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/bmt.2015.222","article-title":"A randomized controlled trial of cyclosporine and tacrolimus with strict control of blood concentrations after unrelated bone marrow transplantation","volume":"51","author":"Kanda","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jaad.2023.05.074_bib66","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/jcph.237","article-title":"Population PKPD of voclosporin in renal allograft patients","volume":"54","author":"Mayo","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jaad.2023.05.074_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.655100","article-title":"What's new in the treatment of systemic lupus erythematosus","volume":"8","author":"Liossis","year":"2021","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.jaad.2023.05.074_bib68","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","article-title":"A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.jaad.2023.05.074_bib69","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jaad.2005.10.061","article-title":"A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis","volume":"54","author":"Bissonnette","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.05.074_bib70","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1684\/ejd.2010.1185","article-title":"Quality of life in plaque psoriasis patients treated with voclosporin: a Canadian phase III, randomized, multicenter, double-blind, placebo-controlled study","volume":"21","author":"Kunynetz","year":"2011","journal-title":"Eur J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.05.074_bib71","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2310\/7750.2008.07060","article-title":"ISA247: quality of life results from a phase II, randomized, placebo-controlled study","volume":"12","author":"Gupta","year":"2008","journal-title":"J Cutan Med Surg"},{"issue":"9621","key":"10.1016\/j.jaad.2023.05.074_bib72","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0140-6736(08)60593-0","article-title":"Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2023.05.074_bib73","series-title":"Isotechnika Announces Phase 3 ESSENCE Data Meets Primary Endpoint in Psoriasis [Webpage on the Internet]","year":"2009"},{"key":"10.1016\/j.jaad.2023.05.074_bib74","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/310329","article-title":"Emerging therapies for noninfectious uveitis: what may be coming to the clinics","volume":"2014","author":"Maya","year":"2014","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.jaad.2023.05.074_bib75","series-title":"Uveitis Treatment Fails Phase 3 Trial [Webpage on the Internet]","year":"2013"},{"issue":"7","key":"10.1016\/j.jaad.2023.05.074_bib84","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/jcph.1082","article-title":"Evaluation of flexible tacrolimus drug concentration monitoring approach in patients receiving extended-release once-daily tacrolimus tablets","volume":"58","author":"Philosophe","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jaad.2023.05.074_bib77","series-title":"Tacrolimus - Drug Monitoring Summary","author":"Pollock","year":"2019"},{"issue":"10","key":"10.1016\/j.jaad.2023.05.074_bib85","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1111\/j.1600-6143.2012.04140.x","article-title":"Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis","volume":"12","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2012","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.jaad.2023.05.074_bib81","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/1759720X11419038","article-title":"The efficacy and safety of tacrolimus in\u00a0rheumatoid arthritis","volume":"3","author":"Dutta","year":"2011","journal-title":"Ther Adv Musculoskelet Dis"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223010800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223010800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T13:07:39Z","timestamp":1723295259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962223010800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":84,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0190962223010800"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.05.074","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic calcineurin inhibitors tacrolimus and voclosporin: A review of off-label dermatologic uses","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.05.074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}